Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
about
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancertAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation
P2860
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@ast
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@en
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@nl
type
label
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@ast
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@en
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@nl
prefLabel
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@ast
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@en
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@nl
P2093
P1433
P1476
Paclitaxel/gemcitabine adminis ...... y results of a phase II trial.
@en
P2093
A Barnadas
A Llombart
V Carañana
Y Fernández
P433
P577
2000-02-01T00:00:00Z